Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

VolitionRx hails 'best yet' in early colorectal cancer detection

In a study of 430 patients in Denmark, the test accurately detected 75% of colorectal adenomas
VolitionRx hails 'best yet' in early colorectal cancer detection
The trial was double blinded and age-adjusted with the results at 78% specificity
VolitionRx (NYSE:VNRX) has published another set of strong trial results for NuQ, its blood test for cancer.
 
In a study of 430 patients in Denmark, the test accurately detected 75% of colorectal adenomas, or pre-cancerous polyps, that were most likely to become cancerous.
 
A panel of five of NuQ biomarker assays also detected 86% of early colorectal cancers.
 
Hvidore University carried out the study to assess how effective was NuQ in detecting adenomas before they become cancerous.
 
The trial was double blinded and age-adjusted with the results at 78% specificity.
 
NuQ uses biomarker assays that can identify fragments of chromosomes, called nucleosomes, circulating in the blood and analyse them for epigenetic modifications that signal that cancer is present. The assays  require only a single drop of blood from patients, Volition added.
 
Professor Hans Jorgen Nielsen, Professor of Surgical Oncology at Hvidovre Hospital said: "This study shows extremely good detection of dangerous pre-cancer and early-stage cancer with the non-invasive NuQ blood test.”
 
We are now working with VolitionRx on large retrospective and prospective trials in both screening and symptomatic populations.
 
Cameron Reynolds, VolitionRx’s chief executive, said: "Not only do these results demonstrate our best detection rates to date for colorectal adenomas, but they further confirm the progress that VolitionRx is making in identifying new NuQ biomarker assays and optimizing panels to produce the most accurate detection rates of adenomas and colorectal cancers.”
 
Talking to Proactive, he added: "Just about every other biomarker out there detects late stage cancer much better than early stage purely because you have a lot more of the marker.
 
"So to have 86% of stage 1 cancers and 75% of pre-cancers is far better than we could have hoped for."
 
He noted particularly that the results of the adenomas, or pre-cancerous polyps were far better than the firm could have hoped for.
 
A commercial product for clinical use in detecting colorectal cancer is expected to be launched later this year.
View full VNRX profile View Profile

VolitionRx Timeline

Newswire
September 14 2017

Related Articles

worried man on bed
October 16 2017
“We are delighted by the results of this new survey, which not only reinforce the potential of MED2002 identified in our two earlier surveys but provide some important additional insights”
m&a icon of bug fish swallowing big fish
December 04 2017
It is paying an initial US$13mln for Vamousse, which it is acquiring from TyraTech, the AIM-listed developer of the range. This will be followed by a deferred pay-out of as much as US$4.5mln based on sales targets
blood cells
October 04 2017
The two parts of the business - the commercial arm and research function - appear to be firing on all cylinders

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use